{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:47Z","timestamp":1790899247574,"version":"4.1.0"},"reference-count":109,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011272","name":"European Commission Seventh Framework Programme for Research and Technological Development Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.tips.2021.04.007","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T08:17:21Z","timestamp":1620807441000},"page":"605-616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Opportunities and challenges for microRNA-targeting therapeutics for epilepsy"],"prefix":"10.1016","volume":"42","author":[{"given":"Gareth","family":"Morris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Henshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2021.04.007_bb0005","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(18)32596-0","article-title":"Epilepsy in adults","volume":"393","author":"Thijs","year":"2019","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.tips.2021.04.007_bb0010","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrd2997","article-title":"Key factors in the discovery and development of new antiepileptic drugs","volume":"9","author":"Bialer","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2021.04.007_bb0015","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/epi.16091","article-title":"Advancing research toward faster diagnosis, better treatment, and end of stigma in epilepsy","volume":"60","author":"Pitk\u00e4nen","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.tips.2021.04.007_bb0020","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/epi.13965","article-title":"Commonalities in epileptogenic processes from different acute brain insults: do they translate?","volume":"59","author":"Klein","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.tips.2021.04.007_bb0025","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/epi.12220","article-title":"International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: a Task Force report from the ILAE Commission on Diagnostic Methods","volume":"54","author":"Bl\u00fcmcke","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.tips.2021.04.007_bb0030","doi-asserted-by":"crossref","first-page":"107605","DOI":"10.1016\/j.neuropharm.2019.04.011","article-title":"The holy grail of epilepsy prevention: preclinical approaches to antiepileptogenic treatments","volume":"167","author":"L\u00f6scher","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tips.2021.04.007_bb0035","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.tips.2020.08.004","article-title":"Paving the road for RNA therapeutics","volume":"41","author":"Dammes","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.tips.2021.04.007_bb0040","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","article-title":"Treatment of HCV infection by targeting microRNA","volume":"368","author":"Janssen","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2021.04.007_bb0045","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-customized oligonucleotide therapy for a rare genetic disease","volume":"381","author":"Kim","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2021.04.007_bb0050","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz6100","article-title":"Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome","volume":"12","author":"Han","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tips.2021.04.007_bb0055","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41586-020-2715-9","article-title":"LifeTime and improving European healthcare through cell-based interceptive medicine","volume":"587","author":"Rajewsky","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.tips.2021.04.007_bb0060","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature01957","article-title":"The nuclear RNase III Drosha initiates microRNA processing","volume":"425","author":"Lee","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.tips.2021.04.007_bb0065","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1093\/emboj\/cdf476","article-title":"MicroRNA maturation: stepwise processing and subcellular localization","volume":"21","author":"Lee","year":"2002","journal-title":"EMBO J."},{"key":"10.1016\/j.tips.2021.04.007_bb0070","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1101\/gad.1158803","article-title":"Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs","volume":"17","author":"Yi","year":"2003","journal-title":"Genes Dev."},{"key":"10.1016\/j.tips.2021.04.007_bb0075","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1126\/science.1090599","article-title":"Nuclear export of microRNA","volume":"303","author":"Lund","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.tips.2021.04.007_bb0080","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.tips.2021.04.007_bb0085","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1126\/science.1064023","article-title":"Argonaute2, a link between genetic and biochemical analyses of RNAi","volume":"293","author":"Hammond","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.tips.2021.04.007_bb0090","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/35005107","article-title":"An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells","volume":"404","author":"Hammond","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.tips.2021.04.007_bb0095","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1126\/science.1073827","article-title":"A microRNA in a multiple-turnover RNAi enzyme complex","volume":"297","author":"Hutvagner","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.tips.2021.04.007_bb0100","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1126\/science.aaa1738","article-title":"MicroRNA control of protein expression noise","volume":"348","author":"Schmiedel","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.tips.2021.04.007_bb0105","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41580-018-0045-7","article-title":"Regulation of microRNA function in animals","volume":"20","author":"Gebert","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.tips.2021.04.007_bb0110","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cell.2018.03.006","article-title":"Metazoan microRNAs","volume":"173","author":"Bartel","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.tips.2021.04.007_bb0115","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.tcb.2015.07.011","article-title":"The functions of microRNAs: mRNA decay and translational repression","volume":"25","author":"Iwakawa","year":"2015","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.tips.2021.04.007_bb0120","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41580-018-0059-1","article-title":"Regulation of microRNA biogenesis and its crosstalk with other cellular pathways","volume":"20","author":"Treiber","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.tips.2021.04.007_bb0125","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.tips.2021.04.007_bb0130","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s41582-020-0369-8","article-title":"MicroRNAs as regulators of brain function and targets for treatment of epilepsy","volume":"16","author":"Brennan","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.tips.2021.04.007_bb0135","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nature04367","article-title":"A brain-specific microRNA regulates dendritic spine development","volume":"439","author":"Schratt","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.tips.2021.04.007_bb0140","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1038\/s41593-018-0265-3","article-title":"Regulation of cell-type-specific transcriptomes by microRNA networks during human brain development","volume":"21","author":"Nowakowski","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.tips.2021.04.007_bb0145","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/WCO.0000000000000079","article-title":"MicroRNA and epilepsy: profiling, functions and potential clinical applications","volume":"27","author":"Henshall","year":"2014","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.tips.2021.04.007_bb0150","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.tins.2012.11.008","article-title":"Glia and epilepsy: excitability and inflammation","volume":"36","author":"Devinsky","year":"2013","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.tips.2021.04.007_bb0155","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/nan.12444","article-title":"Neuroinflammatory pathways as treatment targets and biomarker candidates in epilepsy: emerging evidence from preclinical and clinical studies","volume":"44","author":"van Vliet","year":"2017","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.tips.2021.04.007_bb0160","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.celrep.2016.08.074","article-title":"MicroRNA-mediated downregulation of the potassium channel Kv4.2 contributes to seizure onset","volume":"17","author":"Gross","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.tips.2021.04.007_bb0165","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11910-018-0870-2","article-title":"Regulation of ion channels by microRNAs and the implication for epilepsy","volume":"18","author":"Gross","year":"2018","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.tips.2021.04.007_bb0170","doi-asserted-by":"crossref","first-page":"104508","DOI":"10.1016\/j.nbd.2019.104508","article-title":"MicroRNA inhibition upregulates hippocampal A-type potassium current and reduces seizure frequency in a mouse model of epilepsy","volume":"130","author":"Tiwari","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.tips.2021.04.007_bb0175","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/nrn2763","article-title":"MicroRNAs at the synapse","volume":"10","author":"Schratt","year":"2009","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.tips.2021.04.007_bb0180","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.15252\/embj.201695748","article-title":"A microRNA-129-5p\/Rbfox crosstalk coordinates homeostatic downscaling of excitatory synapses","volume":"36","author":"Rajman","year":"2017","journal-title":"EMBO J."},{"key":"10.1016\/j.tips.2021.04.007_bb0185","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.celrep.2019.09.020","article-title":"Oligodendrocyte intrinsic miR-27a controls myelination and remyelination","volume":"29","author":"Tripathi","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.tips.2021.04.007_bb0190","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1016\/j.celrep.2019.07.071","article-title":"Driving neuronal differentiation through reversal of an ERK1\/2-miR-124-SOX9 axis abrogates glioblastoma aggressiveness","volume":"28","author":"Sabelstr\u00f6m","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.tips.2021.04.007_bb0195","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/s41467-018-03681-3","article-title":"The RNA-binding protein ARPP21 controls dendritic branching by functionally opposing the miRNA it hosts","volume":"9","author":"Rehfeld","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2021.04.007_bb0200","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.brainres.2011.02.073","article-title":"Temporal lobe epilepsy induces differential expression of hippocampal miRNAs including let-7e and miR-23a\/b","volume":"1387","author":"Song","year":"2011","journal-title":"Brain Res."},{"key":"10.1016\/j.tips.2021.04.007_bb0205","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.nbd.2013.10.026","article-title":"Hippocampal subregion-specific microRNA expression during epileptogenesis in experimental temporal lobe epilepsy","volume":"62","author":"Gorter","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.tips.2021.04.007_bb0210","doi-asserted-by":"crossref","first-page":"15977","DOI":"10.1073\/pnas.1919313117","article-title":"A systems approach delivers a functional microRNA catalog and expanded targets for seizure suppression in temporal lobe epilepsy","volume":"117","author":"Ven\u00f8","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2021.04.007_bb0215","doi-asserted-by":"crossref","first-page":"105048","DOI":"10.1016\/j.nbd.2020.105048","article-title":"Genome-wide microRNA profiling of plasma from three different animal models identifies biomarkers of temporal lobe epilepsy","volume":"144","author":"Brennan","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.tips.2021.04.007_bb0220","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1002\/acn3.51146","article-title":"Validation of differentially expressed brain-enriched microRNAs in the plasma of Parkinson\u2019s disease patients","volume":"7","author":"Ravanidis","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.tips.2021.04.007_bb0225","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3390\/genes11090983","article-title":"MicroRNAs modulate the pathogenesis of Alzheimer\u2019s disease: an in silico analysis in the human brain","volume":"11","author":"Gugliandolo","year":"2020","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.tips.2021.04.007_bb0230","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.3390\/ijms21165904","article-title":"Recent progress on relevant microRNAs in autism spectrum disorders","volume":"21","author":"Wu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tips.2021.04.007_bb0235","doi-asserted-by":"crossref","first-page":"101664","DOI":"10.1016\/j.pneurobio.2019.101664","article-title":"microRNA dysregulation in neurodegenerative diseases: a systematic review","volume":"182","author":"Ju\u017awik","year":"2019","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.tips.2021.04.007_bb0240","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3389\/fneur.2020.00663","article-title":"Extracellular vesicle proteins and microRNAs as biomarkers for traumatic brain injury","volume":"11","author":"Guedes","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.tips.2021.04.007_bb0245","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/gt.2013.76","article-title":"ShRNA-induced saturation of the microRNA pathway in the rat brain","volume":"21","author":"Van Gestel","year":"2014","journal-title":"Gene Ther."},{"key":"10.1016\/j.tips.2021.04.007_bb0250","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1016\/j.celrep.2016.02.042","article-title":"Dual and opposing roles of microRNA-124 in epilepsy are mediated through inflammatory and NRSF-dependent gene networks","volume":"14","author":"Brennan","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.tips.2021.04.007_bb0255","first-page":"16","article-title":"Recombinant adeno-associated virus-mediated microRNA delivery into the postnatal mouse brain reveals a role for miR-134 in dendritogenesis in vivo","volume":"3","author":"Christensen","year":"2010","journal-title":"Front. Neural Circuits"},{"key":"10.1016\/j.tips.2021.04.007_bb0260","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1056\/NEJMra1705346","article-title":"Treating disease at the RNA level with oligonucleotides","volume":"380","author":"Levin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2021.04.007_bb0265","doi-asserted-by":"crossref","first-page":"851","DOI":"10.15252\/emmm.201100899","article-title":"Development of microRNA therapeutics is coming of age","volume":"6","author":"Rooij","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.tips.2021.04.007_bb0270","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1261\/rna.448107","article-title":"Double-stranded regions are essential design components of potent inhibitors of RISC function","volume":"13","author":"Vermeulen","year":"2007","journal-title":"RNA"},{"key":"10.1016\/j.tips.2021.04.007_bb0275","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nmeth1079","article-title":"MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells","volume":"4","author":"Ebert","year":"2007","journal-title":"Nat. Methods"},{"key":"10.1016\/j.tips.2021.04.007_bb0280","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkp040","article-title":"Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells","volume":"37","author":"Haraguchi","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tips.2021.04.007_bb0285","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.cell.2012.04.005","article-title":"Roles for microRNAs in conferring robustness to biological processes","volume":"149","author":"Ebert","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.tips.2021.04.007_bb0290","first-page":"97","article-title":"Adenovirus-mediated shRNAs for co-repression of miR-221 and miR-222 expression and function in glioblastoma cells","volume":"25","author":"Wang","year":"2011","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.tips.2021.04.007_bb0295","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1147535","article-title":"Target protectors reveal dampening and balancing of nodal agonist and antagonist by miR-430","volume":"318","author":"Choi","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.tips.2021.04.007_bb0300","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1261\/rna.034850.112","article-title":"Potent microRNA suppression by RNA Pol II-transcribed \u201cTough Decoy\u201d inhibitors","volume":"19","author":"Bak","year":"2013","journal-title":"RNA"},{"key":"10.1016\/j.tips.2021.04.007_bb0305","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nbt.3784","article-title":"Oligonucleotide therapies for disorders of the nervous system","volume":"35","author":"Khorkova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tips.2021.04.007_bb0310","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1089\/ard.1991.1.141","article-title":"Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3\u2032 exonuclease in plasma","volume":"1","author":"Eder","year":"1991","journal-title":"Antisense Res. Dev."},{"key":"10.1016\/j.tips.2021.04.007_bb0315","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1080\/15476286.2018.1445959","article-title":"Anti-miRNA oligonucleotides: a comprehensive guide for design","volume":"15","author":"Lima","year":"2018","journal-title":"RNA Biol."},{"key":"10.1016\/j.tips.2021.04.007_bb0320","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0165-022X(90)90084-P","article-title":"Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid","volume":"20","author":"Campbell","year":"1990","journal-title":"J. Biochem. Biophys. Methods"},{"key":"10.1016\/j.tips.2021.04.007_bb0325","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1093\/nar\/gkw236","article-title":"The delivery of therapeutic oligonucleotides","volume":"44","author":"Juliano","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tips.2021.04.007_bb0330","doi-asserted-by":"crossref","first-page":"17181","DOI":"10.1074\/jbc.M311683200","article-title":"Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs","volume":"279","author":"Wu","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2021.04.007_bb0335","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nbt.3948","article-title":"Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides","volume":"35","author":"Iwamoto","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tips.2021.04.007_bb0340","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1074\/jbc.274.3.1715","article-title":"Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-\u03b1 expression","volume":"274","author":"McKay","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2021.04.007_bb0345","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0022-3565(24)38831-7","article-title":"Pharmacokinetic properties of 2\u2032-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats","volume":"296","author":"Geary","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tips.2021.04.007_bb0350","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1093\/nar\/25.22.4429","article-title":"The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes","volume":"25","author":"Freier","year":"1997","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tips.2021.04.007_bb0355","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/1074-5521(94)90039-6","article-title":"Stabilizing effects of the RNA Y-substituent: structure of an oligodeoxynucleotide adenosines crystal duplex containing","volume":"1","author":"Lubinil","year":"1994","journal-title":"Chem. Biol."},{"key":"10.1016\/j.tips.2021.04.007_bb0360","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0006-2952(95)02177-9","article-title":"Effect of different chemically modified oligodeoxynucleotides on immune stimulation","volume":"51","author":"Zhao","year":"1996","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.tips.2021.04.007_bb0365","doi-asserted-by":"crossref","first-page":"14514","DOI":"10.1016\/S0021-9258(19)85268-7","article-title":"Evaluation of 2\u2032-modified oligonucleotides containing 2\u2032-deoxy gaps as antisense inhibitors of gene expression","volume":"268","author":"Monia","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2021.04.007_bb0370","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1093\/nar\/gkf651","article-title":"Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design","volume":"30","author":"Braasch","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tips.2021.04.007_bb0375","doi-asserted-by":"crossref","first-page":"9973","DOI":"10.1021\/bi025907j","article-title":"Implications of high-affinity hybridization by locked nucleic acid oligomers for inhibition of human telomerase","volume":"41","author":"Elayadi","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.tips.2021.04.007_bb0380","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1081\/NCN-120022731","article-title":"Nuclease stability of LNA oligonucleotides and LNA-DNA chimeras","volume":"22","author":"Frieden","year":"2003","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.tips.2021.04.007_bb0385","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1093\/nar\/30.9.1911","article-title":"Design of antisense oligonucleotides stabilized by locked nucleic acids","volume":"30","author":"Kurreck","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tips.2021.04.007_bb0390","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/nar\/gkl1071","article-title":"Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals","volume":"35","author":"Swayze","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tips.2021.04.007_bb0395","doi-asserted-by":"crossref","first-page":"30613","DOI":"10.1074\/jbc.M603346200","article-title":"Antisense inhibition of RNase P: mechanistic aspects and application to live bacteria","volume":"281","author":"Gruegelsiepe","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2021.04.007_bb0400","doi-asserted-by":"crossref","first-page":"13500","DOI":"10.1021\/ja804727a","article-title":"Oligonucleotide-oligospermine conjugates (zip nucleic acids): a convenient means of finely tuning hybridization temperatures","volume":"130","author":"Noir","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.tips.2021.04.007_bb0405","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0022-3565(25)39459-0","article-title":"Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats","volume":"267","author":"Cossum","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tips.2021.04.007_bb0410","first-page":"948","article-title":"Imaging gene expression in the brain in vivo in a transgenic mouse model of Huntington\u2019s disease with an antisense radiopharmaceutical and drug-targeting technology","volume":"43","author":"Lee","year":"2002","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.tips.2021.04.007_bb0415","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1093\/hmg\/ddr217","article-title":"Arginine-rich cell-penetrating peptide dramatically enhances AMO-mediated ATM aberrant splicing correction and enables delivery to brain and cerebellum","volume":"20","author":"Du","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tips.2021.04.007_bb0420","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.bbamem.2010.02.012","article-title":"Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy","volume":"1798","author":"Moulton","year":"2010","journal-title":"Biochim. Biophys. Acta - Biomembr."},{"key":"10.1016\/j.tips.2021.04.007_bb0425","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1021\/bc070060v","article-title":"Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-Morpholino oligomer conjugate","volume":"18","author":"Amantana","year":"2007","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.tips.2021.04.007_bb0430","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jconrel.2020.08.026","article-title":"Next generation miRNA inhibition using short anti-seed PNAs encapsulated in PLGA nanoparticles","volume":"327","author":"Malik","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.tips.2021.04.007_bb0435","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1007\/s12035-016-9901-7","article-title":"Inhibition of miR-203 reduces spontaneous recurrent seizures in mice","volume":"54","author":"Lee","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.tips.2021.04.007_bb0440","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/nm.2834","article-title":"Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects","volume":"18","author":"Jimenez-Mateos","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2021.04.007_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2021.02.021","article-title":"Systemic delivery of antagomirs during blood-brain barrier disruption is disease-modifying in experimental epilepsy","author":"Reschke","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tips.2021.04.007_bb0450","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1517\/17425250902877680","article-title":"Antisense oligonucleotide pharmacokinetics and metabolism","volume":"5","author":"Geary","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.tips.2021.04.007_bb0455","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.129240","article-title":"Brain pharmacology of intrathecal antisense oligonucleotides revealed through multimodal imaging","volume":"4","author":"Mazur","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.tips.2021.04.007_bb0460","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of Huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.tips.2021.04.007_bb0465","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1124\/jpet.113.212407","article-title":"Pharmacology of a central nervous system delivered 2\u2032-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates","volume":"350","author":"Rigo","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tips.2021.04.007_bb0470","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","article-title":"An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study","volume":"12","author":"Miller","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.tips.2021.04.007_bb0475","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2005056","article-title":"SOD1 suppression with adeno-associated virus and microRNA in familial ALS","volume":"383","author":"Mueller","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2021.04.007_bb0480","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/apt.13432","article-title":"Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma","volume":"43","author":"Van Der Ree","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.tips.2021.04.007_bb0485","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/bioinformatics\/btw008","article-title":"EpimiRBase: a comprehensive database of microRNA-epilepsy associations","volume":"32","author":"Mooney","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.tips.2021.04.007_bb0490","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1007\/s00429-014-0798-5","article-title":"Antagomirs targeting microRNA-134 increase hippocampal pyramidal neuron spine volume in vivo and protect against pilocarpine-induced status epilepticus","volume":"220","author":"Jimenez-Mateos","year":"2015","journal-title":"Brain Struct. Funct."},{"key":"10.1016\/j.tips.2021.04.007_bb0495","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.omtn.2016.11.002","article-title":"Potent anti-seizure effects of locked nucleic acid antagomirs targeting miR-134 in multiple mouse and rat models of epilepsy","volume":"6","author":"Reschke","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.tips.2021.04.007_bb0500","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1111\/epi.14475","article-title":"Spared CA1 pyramidal neuron function and hippocampal performance following antisense knockdown of microRNA-134","volume":"59","author":"Morris","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.tips.2021.04.007_bb0505","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1523\/JNEUROSCI.3014-18.2019","article-title":"Antagonizing increased miR-135a levels at the chronic stage of experimental TLE reduces spontaneous recurrent seizures","volume":"39","author":"Vangoor","year":"2019","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2021.04.007_bb0510","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.neuropharm.2018.06.010","article-title":"Overexpression of miRNA-137 in the brain suppresses seizure activity and neuronal excitability: a new potential therapeutic strategy for epilepsy","volume":"138","author":"Wang","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tips.2021.04.007_bb0515","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3389\/fncel.2019.00145","article-title":"Silencing microRNA-134 alleviates hippocampal damage and occurrence of spontaneous seizures after intraventricular kainic acid-induced status epilepticus in rats","volume":"13","author":"Gao","year":"2019","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.tips.2021.04.007_bb0520","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1101\/gr.146886.112","article-title":"Widespread and extensive lengthening of 3\u2032 UTRs in the mammalian brain","volume":"23","author":"Miura","year":"2013","journal-title":"Genome Res."},{"key":"10.1016\/j.tips.2021.04.007_bb0525","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1038\/s41598-018-22554-9","article-title":"Prolonged life of human acute hippocampal slices from temporal lobe epilepsy surgery","volume":"8","author":"Wickham","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2021.04.007_bb0530","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/epi.12138","article-title":"Canine epilepsy as a translational model?","volume":"54","author":"Potschka","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.tips.2021.04.007_bb0535","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/mp.2013.93","article-title":"Identification of differentially expressed microRNAs across the developing human brain","volume":"19","author":"Ziats","year":"2014","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.tips.2021.04.007_bb0540","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41598-020-79350-7","article-title":"Antagomir-mediated suppression of microRNA-134 reduces kainic acid-induced seizures in immature mice","volume":"11","author":"Campbell","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2021.04.007_bb0545","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/epi.13348","article-title":"Targeting of microRNA-199a-5p protects against pilocarpine-induced status epilepticus and seizure damage via SIRT1-p53 cascade","volume":"57","author":"Wang","year":"2016","journal-title":"Epilepsia"}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614721000778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614721000778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T09:11:59Z","timestamp":1759050719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614721000778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":109,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0165614721000778"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2021.04.007","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opportunities and challenges for microRNA-targeting therapeutics for epilepsy","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2021.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}